NCT06769490View on ClinicalTrials.gov

Dose Escalation and Expansion of Ziftomenib in Combination With Quizartinib in Acute Myeloid Leukemia

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

July 10, 2025

Primary Completion Date

September 15, 2028

Study Completion Date

September 15, 2030

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Ziftomenib

Participants will receive treatment in tablet form

DRUG

Quizartinib

Participants will receive treatment in tablet form

Trial Locations (1)

77030

RECRUITING

The University of Texas M. D. Anderson Cancer Center, Houston

All Listed Sponsors
lead

M.D. Anderson Cancer Center

OTHER